CLINICAL TRIALS PROFILE FOR DESVENLAFAXINE
✉ Email this page to a colleague
All Clinical Trials for DESVENLAFAXINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00256685 ↗ | Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2004-09-01 | The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with menopause, and also to assess the effects of DVS on sleep parameters and health outcomes indicators. |
| NCT00277823 ↗ | Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2006-02-01 | The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects receiving placebo. |
| NCT00283842 ↗ | Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy | Terminated | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2006-03-01 | The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment of neuropathic pain associated with diabetic peripheral neuropathy. |
| NCT00300378 ↗ | Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2006-03-01 | The primary objective is to compare the antidepressant efficacy, safety, and tolerability of DVS SR versus placebo in subjects with Major Depressive Disorder. Additional objectives include testing both general and functional quality-of-life outcomes and satisfaction with therapy reported by the subject. |
| NCT00329147 ↗ | Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2006-05-01 | The purpose of this study is to evaluate the effects of multiple doses of DVS SR and paroxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects. |
| NCT00329186 ↗ | Study Evaluating the Pharmacokinetics of Venlafaxine ER and Desvenlafaxine SR in Healthy Subjects | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2006-05-01 | The purpose of this study is to determine if the relative difference in PK between extensive metabolizers (EMs) and poor metabolizers (PMs) is the same with desvenlafaxine SR and venlafaxine ER when a single dose is administered. |
| NCT00369343 ↗ | Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2006-09-01 | Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of major depressive disorder (MDD), for vasomotor symptoms (VMS) associated with menopause, and for pain associated with peripheral diabetic neuropathy, as well as for the treatment of fibromyalgia syndrome. This study will investigate the safety, efficacy, and tolerability of DVS SR in women with MDD who are peri- and postmenopausal. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DESVENLAFAXINE
Condition Name
Clinical Trial Locations for DESVENLAFAXINE
Trials by Country
Clinical Trial Progress for DESVENLAFAXINE
Clinical Trial Phase
Clinical Trial Sponsors for DESVENLAFAXINE
Sponsor Name
